Ventyx Biosciences (VTYX) Competitors $1.34 +0.02 (+1.13%) As of 12:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTYX vs. CMPS, TKNO, ALLO, TRDA, ARCT, TSHA, HRTX, ATYR, ATAI, and PVLAShould you be buying Ventyx Biosciences stock or one of its competitors? The main competitors of Ventyx Biosciences include COMPASS Pathways (CMPS), Alpha Teknova (TKNO), Allogene Therapeutics (ALLO), Entrada Therapeutics (TRDA), Arcturus Therapeutics (ARCT), Taysha Gene Therapies (TSHA), Heron Therapeutics (HRTX), Atyr PHARMA (ATYR), Atai Life Sciences (ATAI), and Palvella Therapeutics (PVLA). These companies are all part of the "pharmaceutical products" industry. Ventyx Biosciences vs. COMPASS Pathways Alpha Teknova Allogene Therapeutics Entrada Therapeutics Arcturus Therapeutics Taysha Gene Therapies Heron Therapeutics Atyr PHARMA Atai Life Sciences Palvella Therapeutics Ventyx Biosciences (NASDAQ:VTYX) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, risk, valuation, analyst recommendations, dividends, earnings and profitability. Does the media refer more to VTYX or CMPS? In the previous week, COMPASS Pathways had 6 more articles in the media than Ventyx Biosciences. MarketBeat recorded 8 mentions for COMPASS Pathways and 2 mentions for Ventyx Biosciences. COMPASS Pathways' average media sentiment score of 1.31 beat Ventyx Biosciences' score of 1.30 indicating that COMPASS Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ventyx Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive COMPASS Pathways 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, VTYX or CMPS? COMPASS Pathways is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVentyx BiosciencesN/AN/A-$192.96M-$1.98-0.67COMPASS PathwaysN/AN/A-$118.46M-$2.30-1.73 Is VTYX or CMPS more profitable? Ventyx Biosciences' return on equity of -54.94% beat COMPASS Pathways' return on equity.Company Net Margins Return on Equity Return on Assets Ventyx BiosciencesN/A -54.94% -50.01% COMPASS Pathways N/A -63.85%-51.97% Which has more volatility and risk, VTYX or CMPS? Ventyx Biosciences has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.34, suggesting that its stock price is 134% more volatile than the S&P 500. Do insiders & institutionals have more ownership in VTYX or CMPS? 97.9% of Ventyx Biosciences shares are owned by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are owned by institutional investors. 18.2% of Ventyx Biosciences shares are owned by insiders. Comparatively, 4.3% of COMPASS Pathways shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer VTYX or CMPS? COMPASS Pathways received 35 more outperform votes than Ventyx Biosciences when rated by MarketBeat users. Likewise, 81.48% of users gave COMPASS Pathways an outperform vote while only 46.97% of users gave Ventyx Biosciences an outperform vote. CompanyUnderperformOutperformVentyx BiosciencesOutperform Votes3146.97% Underperform Votes3553.03% COMPASS PathwaysOutperform Votes6681.48% Underperform Votes1518.52% Do analysts rate VTYX or CMPS? Ventyx Biosciences currently has a consensus price target of $10.00, suggesting a potential upside of 651.88%. COMPASS Pathways has a consensus price target of $20.20, suggesting a potential upside of 407.54%. Given Ventyx Biosciences' higher possible upside, research analysts plainly believe Ventyx Biosciences is more favorable than COMPASS Pathways.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ventyx Biosciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75COMPASS Pathways 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCOMPASS Pathways beats Ventyx Biosciences on 8 of the 15 factors compared between the two stocks. Get Ventyx Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for VTYX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTYX vs. The Competition Export to ExcelMetricVentyx BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$91.09M$6.89B$5.56B$7.82BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.567.4422.5118.48Price / SalesN/A242.70395.68103.60Price / CashN/A65.8538.1834.62Price / Book0.326.516.774.25Net Income-$192.96M$143.21M$3.22B$248.23M7 Day Performance5.56%1.98%1.45%0.89%1 Month Performance24.30%6.89%3.97%3.53%1 Year Performance-71.58%-2.52%16.14%5.08% Ventyx Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTYXVentyx Biosciences2.5071 of 5 stars$1.35+1.1%$10.00+643.5%-64.4%$95.71MN/A-0.5730Upcoming EarningsNews CoveragePositive NewsCMPSCOMPASS Pathways2.4309 of 5 stars$3.38+8.0%$20.20+497.6%-53.6%$313.24MN/A-1.54120Upcoming EarningsNews CoveragePositive NewsTKNOAlpha Teknova1.8897 of 5 stars$5.78+0.3%$8.50+47.1%+274.7%$308.87M$37.75M-7.81240News CoverageALLOAllogene Therapeutics3.4292 of 5 stars$1.42-2.1%$9.29+554.1%-39.1%$308.52M$22,000.00-0.91310Positive NewsTRDAEntrada Therapeutics2.9936 of 5 stars$7.95-2.2%$25.67+222.9%-23.0%$298.88M$210.78M5.00110Upcoming EarningsNews CoverageHigh Trading VolumeARCTArcturus Therapeutics2.9865 of 5 stars$11.00+4.5%$59.20+438.2%-49.9%$298.32M$138.39M-4.95180Upcoming EarningsNews CoveragePositive NewsTSHATaysha Gene Therapies1.9643 of 5 stars$1.45+16.9%$6.63+356.9%-20.2%$297.33M$8.33M2.30180Analyst ForecastNews CoverageHRTXHeron Therapeutics3.727 of 5 stars$1.93+4.9%$5.67+193.6%+4.3%$294.00M$144.29M-10.72300Upcoming EarningsNews CoverageATYRAtyr PHARMA2.3923 of 5 stars$3.28+5.8%$18.60+467.1%N/A$291.46M$235,000.00-3.4953Short Interest ↑News CoverageATAIAtai Life Sciences2.6873 of 5 stars$1.42-3.4%$10.50+639.4%-24.2%$283.69M$308,000.00-1.7580Positive NewsPVLAPalvella Therapeutics3.4225 of 5 stars$25.45+4.5%$44.43+74.6%N/A$280.43M$42.81M-2.10N/AAnalyst ForecastHigh Trading Volume Related Companies and Tools Related Companies COMPASS Pathways Competitors Alpha Teknova Competitors Allogene Therapeutics Competitors Entrada Therapeutics Competitors Arcturus Therapeutics Competitors Taysha Gene Therapies Competitors Heron Therapeutics Competitors Atyr PHARMA Competitors Atai Life Sciences Competitors Palvella Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTYX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ventyx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ventyx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VTYX Stock Free VTYX Stock Alerts